DC passes pharma rep licensing bill

Soon, pharma sales folk could be ticketed for repping without a license. The District of Columbia's governing council voted to require sales reps to obtain licenses, becoming the only jurisdiction in the country to do so.

The vote was close--seven to six. And the final measure lacked a provision that would have prohibited data-mining of doctors' prescribing habits. Nevertheless, the primary provision stands. Once licensed, reps could be suspended for fraudulent behavior.

- read the article in the Washington Post
- here's more from the Washington Business Journal

Related Articles:
DC to vote on rep-licensing bill. Report
Dr. Drug Rep tells all. Report
Top Lilly exec plays secret sales agent. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.